Evaluation of potentially inappropriate medication of novel oral anticoagulant in elderly patients with non-valvular atrial fibrillation
10.12173/j.issn.1005-0698.202411064
- VernacularTitle:高龄非瓣膜性心房颤动患者新型口服抗凝药物的潜在不适当用药研究
- Author:
Yan WANG
1
;
Weiwei TIAN
1
;
Haibin ZHU
1
;
Zicheng YU
1
Author Information
1. 同济大学附属杨浦医院药学部(上海 200090)
- Publication Type:Journal Article
- Keywords:
Novel oral anticoagulants;
Elderly patient;
Non-valvular atrial fibrillation;
Potential inappropriate medication
- From:
Chinese Journal of Pharmacoepidemiology
2025;34(1):21-26
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the application of novel oral anticoagulants(NOACs)in the treatment of elderly patients with non-valvular atrial fibrillation(NVAF),and to provide a basis for the rational use of drugs in clinical practice.Methods Based on the Beers criteria(2023 edition),combined with drug instructions and relevant guidelines,the potential inappropriate medication(PIM)evaluation criteria of NOACs in NVAF patients were formulated.The medication PIM of patients aged 80 years or older who were hospitalized in the cardiovascular department from January to December 2023 was analyzed when using NOACs.Results A total of 78 cases were included,and 47 cases of PIM occurred in NOACs,including 1 case of renal function-related PIM(2.13％),and 46 cases of drug interaction related PIM(97.87％).There were 72 patients who do not meet the evaluation criteria of the 2023 version of the Beers standard.Conclusion The updated Beers standard has not yet been widely adopted in clinical practice.The highest incidence of PIM in the use of NOACs in elderly patients with NVAF is due to drug interactions.It is necessary to strengthen drug monitoring in elderly patients with NVAF and promote rational drug use.
